Claims

1. A transdermal preparation comprising drug to be delivered through skin and adhesive, which is characterized in that the said drug is hydrophilic or salt form and the said adhesive has poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether at side chain.
2. The transdermal preparation according to Claim 1, wherein one or more components selected from a group consisting of solubilizer and skin permeation enhancer are further comprised.
3. The transdermal preparation according to Claim 1 or 2, wherein the content of the said drug is in a range of 1-50% by weight based on the total weight of the adhesive layer.
4. The transdermal preparation according to Claim 1 or 2, wherein the molecular weight of the said poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether is in a range of 100-30000, and the content thereof is in a range of 0.01-50% by weight based on the total weight of polymeric adhesive.
5. The transdermal preparation according to Claim 4, wherein the molecular weight of the said poly(ethylene oxide) or poly(ethylene oxide) monomethyl ether is in a range of 400-5000, and the content thereof is in a range of 0.05-30 % by weight based on the total weight of polymeric adhesive.
6. The transdermal preparation according to Claim 1 or 2, wherein the said drug is selected from a group consisting of sodium, potassium and diethylammonium salts of diclofenac, amfenac, aceclofenac and alclofenac; ketorolac tromethamine; hydrochloride, phosphate and methanesulfonate salts of eperisone and tolperisone; oxybutynin chloride; hydrochloride, hydrobromate, fumarate, succinate and tartrate salts of diphenhydramine, ketotifen, doxylamine,

promethazine and trimeprazine; hydrochloride and sulfate salts of tulobuterol, clenbuterol, procaterol and terbutaline; acetate, succinate, valerate and disodium phospate salts of hydrocortisone, dexamethasone and betamethasone; hydrochloride salts of ondansetron, granisetron and ramosetron.

7. The transdermal preparation according to Claim 2, wherein the solubilizer is at least one component selected from a group consisting of ethanol, isopropanol, poly(ethylene glycol), ethoxydiglycol, distilled water, propylene glycol, glycerin and dimethylsulfoxide, and the content is in a range of 0.5-50% by weight based on adhesive layer,

8. The transdermal preparation according to Claim 2, wherein the skin permeation enhancer is at least one component selected from a group consisting of higher fatty acids; higher alcohols; higher fatty acid esters; fatty acid esters; fatty acid ethers of poly(ethylene glycol); fatty acid esters of poly(ethylene glycol); fatty acid ethers of propylene glycol; fatty acid esters of propylene glycol; sorbitan fatty acid esters; poly(ethylene glycol) sorbitan fatty acid esters; terpenes; sulfoxides; pyrrolidones; amides; and N-hydroxy methyl lactate, sorbitol, urea, squalene, olive oil, mineral oil and its derivative, and the content is in a range of 0.5-50% by weight based on the adhesive layer.

9. The transdermal preparation according to Claim 8, wherein the skin permeation enhancer is at least one component selected from a group consisting of lauric acid, oleic acid, lauryl alcohol, oleyl alcohol, glycerol monolaurate, glycerol monooleate, polyoxyethylene(2) lauryl ether, polyoxyethylene(2) oleyl ether, propylene glycol monolaurate, propylene glycol monooleate, sorbitan monolaurate, sorbitan monooleate, lauryl diethanolamide, N-methyl-2-pyrrolidone and isopropyl myristate.

10. The transdermal preparation according to Claims 7 to 9, wherein the each content of the said solubilizer and said skin permeation enhancer is in range of 1-30% by weight based on the adhesive layer.